| Target Price | $202.07 |
| Price | $100.60 |
| Potential | 100.87% |
| Number of Estimates | 25 |
| 25 Analysts have issued a price target Insmed Incorporated 2027 . The average Insmed Incorporated target price is $202.07. This is 100.87% higher than the current stock price. The highest price target is $255.15 153.63% , the lowest is $170.69 69.67% . | |
| A rating was issued by 30 analysts: 29 Analysts recommend Insmed Incorporated to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Insmed Incorporated stock has an average upside potential 2027 of 100.87% . Most analysts recommend the Insmed Incorporated stock at Purchase. |
25 Analysts have issued a sales forecast Insmed Incorporated 2026 . The average Insmed Incorporated sales estimate is
This results in the following potential growth metrics:
8 Analysts have issued an Insmed Incorporated EBITDA forecast 2026. The average Insmed Incorporated EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
25 Insmed Incorporated Analysts have issued a net profit forecast 2026. The average Insmed Incorporated net profit estimate is
This results in the following potential growth metrics and future Net Margins:
25 Analysts have issued a Insmed Incorporated forecast for earnings per share. The average Insmed Incorporated EPS is
This results in the following potential growth metrics and future valuations:
Insmed Incorporated...
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Barclays |
Overweight
➜
Overweight
|
Unchanged | Sep 30 2026 |
| Goldman Sachs |
➜
Buy
|
Unchanged | Sep 24 2026 |
| Roth Capital |
Buy
➜
Buy
|
Unchanged | Sep 15 2026 |
| Truist Securities |
Buy
➜
Buy
|
Unchanged | Aug 10 2026 |
| JP Morgan |
Overweight
➜
Overweight
|
Unchanged | Aug 10 2026 |
| Evercore ISI Group |
Outperform
➜
Outperform
|
Unchanged | Aug 07 2026 |
| Guggenheim |
Buy
➜
Buy
|
Unchanged | Aug 07 2026 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Barclays:
Overweight
➜
Overweight
|
Sep 30 2026 |
|
Unchanged
Goldman Sachs:
➜
Buy
|
Sep 24 2026 |
|
Unchanged
Roth Capital:
Buy
➜
Buy
|
Sep 15 2026 |
|
Unchanged
Truist Securities:
Buy
➜
Buy
|
Aug 10 2026 |
|
Unchanged
JP Morgan:
Overweight
➜
Overweight
|
Aug 10 2026 |
|
Unchanged
Evercore ISI Group:
Outperform
➜
Outperform
|
Aug 07 2026 |
|
Unchanged
Guggenheim:
Buy
➜
Buy
|
Aug 07 2026 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


